ERBB2 and neoplasm: CONCEPTUAL ADVANCE: This study provides further insight into the mechanisms underlying resistance to anti-HER2 therapy by identifying a therapy-associated, stroma-related adaptive response that may contribute to reduced treatment sensitivity beyond tumour-intrinsic alterations.